S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature.
Apostolia Maria Tsimberidou,Jorge Medina,Jorge E. Cortes,Adan Rios,Glisson Bonnie,Stefan Faderl,Hagop M. Kantarjian,Guillermo Garcia-Manero +7 more
TL;DR: It appears that there is no in vivo interaction between imatinib and highly active anti-retroviral therapy (HAART) and these drugs can be concurrently administered with safety to patients with CML and AIDS.
Journal ArticleDOI
Phase I Study of the Combination of 5-Azacitidine Sequentially with High-Dose Lenalidomide in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Guillermo Garcia-Manero,Naval Daver,Gautam Borthakur,Marina Konopleva,Farhad Ravandi,William G. Wierda,Zeev Estrov,Stefan Faderl,Tapan M. Kadia,Kristy Rey,Cora M. Cheung,Hagop M. Kantarjian +11 more
TL;DR: The combination of 5-azacitidine with high dose LEN up to 75 mg orally × 10 days is safe in patients with AML/MDS and the maximal tolerated dose was therefore not reached.
Journal ArticleDOI
Hematopoietic recovery following induction therapy of acute leukemias: prognostic implications and a new look at the definition of remission.
Stefan Faderl,Zeev Estrov +1 more
TL;DR: Shorter time to platelet recovery in patients achieving CR has been demonstrated to be associated with longer overall and disease-free survival in patients with acute lymphoblastic leukemia (ALL), including Philadelphia chromosome-positive ALL.
Journal ArticleDOI
Phase I Study of the Oral Histone Deacetylase Inhibitor SB939 In Patients with Advanced Hematologic Malignancies
Guillermo Garcia-Manero,Charles Chuah,George Wilding,Julie Chang,Srdan Verstovsek,Stefan Faderl,Hagop M. Kantarjian,Kantharaj Ethirajulu,Joy Zhu +8 more
TL;DR: A phase I, open label, dose escalation study in patients with advanced hematologic malignancies was conducted to assess the safety, maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics and preliminary efficacy of SB939.
Journal ArticleDOI
Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia.
Paolo Strati,Alessandra Ferrajoli,Susan Lerner,Susan O'Brien,William G. Wierda,Michael J. Keating,Stefan Faderl +6 more
TL;DR: Combining Granulocyte macrophage colony-stimulating factor with FCR led to a lower frequency of infectious complications than in the historical FCR group, albeit similar EFS and OS.